Compare GVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | APGE |
|---|---|---|
| Founded | 1922 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 1990 | 2023 |
| Metric | GVA | APGE |
|---|---|---|
| Price | $116.14 | $77.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $105.00 | $100.00 |
| AVG Volume (30 Days) | 634.1K | ★ 818.6K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 68.53 | N/A |
| EPS | ★ 3.67 | N/A |
| Revenue | ★ $4,236,312,000.00 | N/A |
| Revenue This Year | $11.29 | N/A |
| Revenue Next Year | $10.61 | N/A |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $69.08 | $26.20 |
| 52 Week High | $115.88 | $78.12 |
| Indicator | GVA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 79.75 | 73.47 |
| Support Level | $107.77 | $74.48 |
| Resistance Level | $110.31 | $76.87 |
| Average True Range (ATR) | 2.43 | 3.37 |
| MACD | 1.04 | -0.06 |
| Stochastic Oscillator | 89.23 | 91.13 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.